Abstract

BackgroundInformation on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce.ObjectivesWe aimed to analyze the retention rate and safety of IXE in patients...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience.
Stefanie Burger ... Pablo González Del Pozo
Journal of clinical medicine | VOL. 12
Stefanie Burger, et. al.Stefanie Burger ... Pablo González Del Pozo
06 Jan 2023
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
Ana-Maria Orbai ... Amanda M Gellett
Rheumatology and therapy | VOL. 8
Ana-Maria Orbai, et. al.Ana-Maria Orbai ... Amanda M Gellett
05 Dec 2020
Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis.
Tianhui Yang ... Hui Wang
Chinese medical journal | VOL. 136
Tianhui Yang, et. al.Tianhui Yang ... Hui Wang
05 Feb 2023
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
David Sandoval ... So Young Park
Clinical Rheumatology | VOL. 41
David Sandoval, et. al.David Sandoval ... So Young Park
08 Jun 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers